Olverembatinib (HQP1351) in Combination with Lisaftoclax Overcomes Venetoclax Resistance in Preclinical Model of Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Xiong, Yan [1 ]
Liang, Zhiyan [2 ]
Min, Ping [1 ]
Wu, Bingxing [1 ]
Yu, Huidan [1 ]
Yang, Dajun [1 ,2 ,3 ]
Zhai, Yifan [1 ,2 ]
机构：
[1] Ascentage Pharm Suzhou Co Ltd, Suzhou, Peoples R China
[2] Ascentage Pharm Grp Inc, Rockville, MD USA
[3] Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-202699
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5777 / 5778
页数：2
相关论文
共 50 条
  • [1] Combination of Liposomal Mitoxantrone, Venetoclax, Homoharringtonine, and Olverembatinib (HQP1351) (MVHO) in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia (AML): Case Series
    Hu, Wenting
    Wang, Zhuo
    Chen, Changcheng
    Shen, Shuhong
    BLOOD, 2023, 142
  • [2] Combination of olverembatinib (HQP1351) with BCL-2 inhibitor lisaftoclax (APG-2575) overcomes resistance in gastrointestinal stromal tumors (GISTs)
    Min, Ping
    Wang, Guangfeng
    Liang, Eric
    Wu, Bingxing
    Yu, Huidan
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
    Zhai, Yifan
    Tang, Qiuqiong
    Fang, Douglas D.
    Deng, Jing
    Zhang, Kaixiang
    Wang, Qixin
    Yin, Yan
    Fu, Chengcheng
    Xue, Sheng -Li
    Li, Na
    Zhou, Feng
    Yang, Dajun
    CLINICAL CANCER RESEARCH, 2023, 29 (01) : 183 - 196
  • [4] Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia
    Zhang, Tongtong
    Zhou, Haixia
    Xu, Mingzhu
    Qian, Chongsheng
    Sun, Aining
    Wu, Depei
    Xue, Shengli
    ANNALS OF HEMATOLOGY, 2023, 102 (04) : 973 - 975
  • [5] Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/ Refractory Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Jabbour, Elias
    Oehler, Vivian G.
    Koller, Paul B.
    Jamy, Omer
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Mukherjee, Sudipto
    Cortes, Jorge E.
    Baer, Maria R.
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Guo, Huanshan
    Chen, Zi
    Fu, Tommy
    Jiang, Lixin
    Wang, Cunlin
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S371 - S371
  • [6] Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia
    Tongtong Zhang
    Haixia Zhou
    Mingzhu Xu
    Chongsheng Qian
    Aining Sun
    Depei Wu
    Shengli Xue
    Annals of Hematology, 2023, 102 : 973 - 975
  • [7] Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph plus ALL)
    Jabbour, Elias
    Koller, Paul B.
    Oehler, Vivian G.
    Jamy, Omer H.
    Mukherjee, Sudipto
    Hunter, Anthony M.
    Baer, Maria R.
    Beck, Joseph T.
    Chen, Zi
    Guo, Huanshan
    Fu, Lei
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    Jiang, Lixin
    Wang, Cunlin
    BLOOD, 2022, 140
  • [8] Exposure-Response (E-R) Analysis of Olverembatinib (HQP1351) in Chinese Patients with Chronic Myeloid Leukemia (CML)
    Lu, Ming
    Deng, Chenhui
    Xiong, Yifeng
    Wang, Hengbang
    Xu, Ping
    Men, Lichuang
    Xie, Tanhong
    Jiang, Qian
    Chen, Zi
    Niu, Qian
    Liu, Ping
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2020, 136
  • [9] FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia
    Fang, Douglas D.
    Zhu, Hengrui
    Tang, Qiuqiong
    Wang, Guangfeng
    Min, Ping
    Wang, Qixin
    Li, Na
    Yang, Dajun
    Zhai, Yifan
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [10] HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models
    Wang, Guangfeng
    Qiu, Haibo
    Min, Ping
    Wu, Miaoyi
    Dang, Shuo
    Yang, Chunyang
    Zhang, Fei
    Zhuang, Wei
    Zhou, Zhiwei
    Fang, Douglas D.
    Yang, Dajun
    Zhai, Yifan
    CANCER RESEARCH, 2018, 78 (13)
12345